The in vivo efficacy of emavusertib in B-cell NHL was first evaluated in an OCI-Ly3 xenograft model (xenograft model of ABC DLBCL with MYD88-L265P mutation) through once daily oral administration. This evidence concerns the gene MYD88 and B-cell non-Hodgkin lymphoma.